- |||||||||| Journal: Chronic Prurigo. (Pubmed Central) - Jun 10, 2024
It also highlights other agents currently being studied in Phase II and Phase III clinical, randomized, placebo-controlled trials. These include biologics such as nemolizumab (anti-IL-31-RA-mAb), vixarelimab/KPL-716 (anti-Oncostatin-M receptor ?-mAb), and barzolvolimab/CDX-0159 (anti-KIT-mAb), as well as Janus kinase inhibitors such as povorcitinib/INCB054707 and abrocitinib, and opioid modulators such as nalbuphine.
- |||||||||| Arcalyst (rilonacept) / Regeneron, Kiniksa
Journal, Patient reported outcomes: Interleukin-1 blockers for the treatment of recurrent pericarditis: pathophysiology, patient reported outcomes and perspectives. (Pubmed Central) - Jun 6, 2024
The early experience of IL-1 blockade with anakinra (Kineret) and its favorable safety profile paved the way for the clinical development of rilonacept (Arcalyst) and subsequent approval by the US FDA for RP. In patients with RP who have become colchicine-resistant and glucocorticoid-dependent, IL-1 blockade with rilonacept or anakinra effectively treats recurrences and prevents future flares, and significantly improves quality of life.
- |||||||||| Arcalyst (rilonacept) / Regeneron, Kiniksa
RILONACEPT USE IN LUPUS PERICARDITIS () - May 29, 2024 - Abstract #EULAR2024EULAR_3309;
Rilonacept successfully treated lupus pericarditis in this case series. Rilonacept should be considered for the treatment of lupus pericarditis.
- |||||||||| goflikicept (RPH-104) - R / Pharm, Arcalyst (rilonacept) / Regeneron, Kiniksa
Journal: Goflikicept and Related IL-1 Inhibitors in the Treatment of Recurrent Pericarditis. (Pubmed Central) - May 6, 2024
In patients with recurrences, the mean time to flare was 28.4 days in the placebo group versus 76.5 days in the anakinra group. IL-1 inhibitors require further research and have the potential to decrease the use of first-line drug regimens for recurrent pericarditis that are not tolerated in specific patient groups.
- |||||||||| Review, Journal: Interleukin inhibitors and the associated risk of candidiasis. (Pubmed Central) - Apr 16, 2024
In contrast, tocilizumab, an inhibitor of IL-6, has demonstrated an elevated risk in the context of coronavirus disease 2019 (COVID-19) treatment, as evidenced by a 6.9% prevalence of candidemia among patients using the drug...Future prospective studies need to exhaustively investigate candidiasis and its associated risk factors in patients receiving IL inhibitors. Implementing enduring surveillance methods is crucial to ensure IL inhibitors safe and efficient utilization of in clinical settings.
- |||||||||| Arcalyst (rilonacept) / Regeneron, Kiniksa
Journal: Rilonacept use in lupus pericarditis. (Pubmed Central) - Mar 25, 2024
Rilonacept successfully treated lupus pericarditis in this case series. Rilonacept should be considered for the treatment of lupus pericarditis.
- |||||||||| Arcalyst (rilonacept) / Regeneron, Kiniksa
Journal: Sustained Pericarditis Recurrence Risk Reduction With Long-Term Rilonacept. (Pubmed Central) - Mar 20, 2024
P3
Rilonacept should be considered for the treatment of lupus pericarditis. In the RHAPSODY long-term extension, continued rilonacept treatment resulted in continued response; treatment suspension at the 18-month decision milestone was associated with pericarditis recurrence.
- |||||||||| Kineret (anakinra) / SOBI, Arcalyst (rilonacept) / Regeneron, Kiniksa, Ilaris (canakinumab) / Novartis
Journal: Practical Approach to Diagnosis and Management of IL-1-Mediated Autoinflammatory Diseases (CAPS, TRAPS, MKD, and DIRA). (Pubmed Central) - Feb 26, 2024
Recently published provisional points to consider from the European Alliance of Associations for Rheumatology (EULAR) and American College of Rheumatology (ACR) provide diagnosis, management, and monitoring recommendations for four IL-1-mediated autoinflammatory diseases: cryopyrin-associated periodic syndromes (CAPS), tumour necrosis factor receptor-associated periodic syndrome (TRAPS), mevalonate kinase deficiency (MKD), and deficiency of the IL-1 receptor antagonist (DIRA). The goal of this paper is to aid health care professionals by providing a practical approach to diagnosis and management of these four IL-1 mediated SAIDs on the basis of the recent EULAR/ACR recommendations.
- |||||||||| Arcalyst (rilonacept) / Regeneron, Kiniksa
Rilonacept use in lupus pericarditis () - Feb 25, 2024 - Abstract #LUPUS2024LUPUS_335;
Conclusion Rilonacept successfully treated lupus pericarditis in this case series. Rilonacept should be considered for the treatment of lupus pericarditis.
- |||||||||| Review, Journal: Biomaterials Functionalized with Inflammasome Inhibitors-Premises and Perspectives. (Pubmed Central) - Feb 23, 2024
Moreover, phytochemicals inhibit the inflammasomes by neutralizing reactive oxygen species. Biomaterials functionalized by the adsorption of therapeutic agents onto different nanomaterials could represent future research directions to facilitate multimodal and sequential treatment in oral pathologies.
- |||||||||| Dupixent (dupilumab) / Sanofi, Regeneron, vixarelimab (RG6536) / Roche, Mitchga (nemolizumab) / Roche, Maruho, Galderma
Biologic and Oral Small Molecule Treatment for Prurigo Nodularis: An Evidence-Based Review () - Feb 20, 2024 - Abstract #AAD2024AAD_2230;
These results indicate dupilumab and tofacitinib may be efficacious and safe agents for clearance of PN with nemolizumab and vixarelimab being additional options for reduction of pruritus. Larger-scale studies are warranted.
- |||||||||| Kineret (anakinra) / SOBI, Arcalyst (rilonacept) / Regeneron, Kiniksa, Ilaris (canakinumab) / Novartis
IL-1 () - Feb 20, 2024 - Abstract #AAD2024AAD_2215;
Objectives We performed a systematic review of prospective and retrospective studies, as well as case reports and series, to determine whether IL-1? inhibitors (canakinumab, anakinra and rilonacept) improve patients
- |||||||||| vixarelimab (RG6536) / Roche, Mitchga (nemolizumab) / Roche, Maruho, Galderma
Review, Journal: A systematic review of interleukin-31 inhibitors in the treatment of prurigo nodularis. (Pubmed Central) - Feb 9, 2024
IL-31 inhibitors suggest distinct advantages in improving pruritus, sleep quality, and overall quality of life in subjects with moderate-to-severe PN. Further clinical studies are recommended to compare the effectiveness of these biologics to other therapeutic choices.
- |||||||||| Arcalyst (rilonacept) / Regeneron, Kiniksa
A RARE CASE OF RECURRENT PERICARDITIS COMPLICATED BY APLASTIC ANEMIA TREATED WITH IL-1 INHIBITOR RILONACEPT (Hall B4-5) - Jan 26, 2024 - Abstract #ACC2024ACC_7362;
The RHAPSODY phase III clinical trial has shown that Rilonacept can reduce symptoms, inflammatory markers, and episodic recurrence in patients with recurrent pericarditis. Patient's who are intolerant to or cannot take colchicine, an agent such as Rilonacept can be initiated as either a monotherapy or in combination with the steroid taper for symptom resolution.
- |||||||||| Arcalyst (rilonacept) / Regeneron, Kiniksa
HEARTACHE UNVEILED: A CASE OF RECURRENT PERICARDITIS PRESENTING WITH TAKOTSUBO CARDIOMYOPATHY (Hall B4-5) - Jan 26, 2024 - Abstract #ACC2024ACC_7290;
Inflammatory markers were subsequently found to be elevated and she was started on colchicine and high dose ibuprofen...She was scheduled for follow up to discuss potential need for rilonacept in order to prevent recurrent pericarditis.Decision?making: Numerous stressors have been implicated as causes of TCM. This case highlights the potential relation between recurrent pericarditis and takotsubo.
- |||||||||| Arcalyst (rilonacept) / Regeneron, Kiniksa
RILONACEPT AFTER PULMONARY VEIN ISOLATION: AN UNCHARTED TERRITORY (Hall B4-5) - Jan 26, 2024 - Abstract #ACC2024ACC_5384;
She failed to tolerate Indomethacin which was started on discharge at the OSH. Rilonacept should be considered as an effective management strategy in PCIS patients.
- |||||||||| Arcalyst (rilonacept) / Regeneron, Kiniksa
PERIMYOCARDITIS WITH CARDIOGENIC SHOCK TREATED WITH RILONACEPT (Hall B4-5) - Jan 26, 2024 - Abstract #ACC2024ACC_3297;
Over the ensuing six months she experienced recurrent perimyocarditis while on colchicine and corticosteroid therapy. Rilonacept is an anti-inflammatory agent that should be considered and further investigated in patients with not only pericarditis, but also those with myocardial involvement.
- |||||||||| Arcalyst (rilonacept) / Regeneron, Kiniksa
FIRST DESCRIBED RILONACEPT CESSATION STRATEGY IN PATIENTS WITH CHRONIC RECURRENT PERICARDITIS (Hall B4-5) - Jan 26, 2024 - Abstract #ACC2024ACC_652;
While our study is ongoing, even with the brief follow-up, abrupt taper was associated with more recurrence rate versus slow taper. Thus, in patients showing improvement in activity, inflammatory markers and MRI findings after 18 months of RI, a slow taper may be useful.
- |||||||||| Arcalyst (rilonacept) / Regeneron, Kiniksa
First Reported Case of SLE Associated Recurrent Pericarditis Treated With Rilonacept (Zone 2, Science and Technology Hall, Level 2) - Sep 21, 2023 - Abstract #AHA2023AHA_8145;
Our patient's positive response to Rilonacept suggests the presence of additional target pathways in autoimmune diseases that may mediate pericarditis recurrence. Future prospective studies are needed to elucidate this further.
- |||||||||| Review, Journal: Chronic Prurigo Including Prurigo Nodularis: New Insights and Treatments. (Pubmed Central) - Sep 17, 2023
In the last past 15 years, several milestones have been reached regarding the disease understanding of CPG such as first transcriptomic analysis, first terminology, first guideline, and first therapy approval in 2022, which contributed to improved medical care of affected patients. The broad range of identified targets, current case observations and initiated trials offers the possibility of more drug approvals in the near future.
- |||||||||| Kineret (anakinra) / SOBI, Arcalyst (rilonacept) / Regeneron, Kiniksa, Ilaris (canakinumab) / Novartis
Journal: IL-1 blockade in cardiovascular disease: an appraisal of the evidence across different inflammatory paradigms. (Pubmed Central) - Sep 14, 2023
In conclusion, the NLRP3 inflammasome and IL-1 contribute to the pathophysiology of CV diseases, and IL-1 blockade is beneficial with different roles in the acute injury, chronic inflammation and autoinflammatory disease paradigms. Further research is needed to guide the optimal use of IL-1 blockers in clinical practice.
- |||||||||| Arcalyst (rilonacept) / Regeneron, Kiniksa
Review, Journal: Paradigm Shift in Diagnosis and Targeted Therapy in Recurrent Pericarditis. (Pubmed Central) - Aug 31, 2023
Understanding the role of the inflammasome via the autoinflammatory pathway in pericarditis has led to incorporation of IL-1 inhibitors in the treatment of recurrent pericarditis, with proven efficacy and safety and randomized trials. This will lead to increase uptake of this agent which demonstrated lower rates of recurrence and faster time to resolution.
- |||||||||| Arcalyst (rilonacept) / Regeneron, Kiniksa
A Rare Case of Pericarditis as an Initial Manifestation of Rheumatoid Arthritis (Zone 2, Science and Technology Hall, Level 2) - Aug 12, 2023 - Abstract #AHA2023AHA_6067;
This case highlights the possibility of idiopathic pericarditis evolving into an autoimmune etiology, such as RA, over time. The combination of rilonacept and azathioprine for treating RA has limited evidence, emphasizing the need for further research in this area.
- |||||||||| Arcalyst (rilonacept) / Regeneron, Kiniksa
Post-Cardiac Injury Syndrome From Robotic Atrial Septal Defect Closure: A Case of Recurrent Pericarditis (Zone 2, Science and Technology Hall, Level 2) - Aug 12, 2023 - Abstract #AHA2023AHA_6065;
Her subsequent recurrences occurred with playing rugby and were treated with ibuprofen, colchicine, and prednisone...She was diagnosed with chronic recurrent pericarditis secondary to post-cardiac injury syndrome (PCIS) and was started on rilonacept...The risk of recurrences with physical activity is debated and current guidelines recommend restriction from physical activity until there is no evidence of active disease, though the data is not robust. In clinical practice, a gradual return-to-play program is frequently utilized.
|
